CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| ALTE05N1 | COG | Umbrella Long-Term Follow-Up Protocol | Pediatric CIRB | Available to Open |
| AALL06N1 | COG | A Study of Neurocognitive Function in Children Treated for ALL: A Group-wide; Non-Therapeutic Companion Study to AALL0232 | Pediatric CIRB | Completed |
| ANHL1131 | COG | Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients | Pediatric CIRB | Completed |
| D9902 | COG | Early Onset Malignancies Initiative (EOMI): Molecular profiling of Breast, Colon, Kidney, Liver, Multiple Myeloma, and Prostate among Racially and Ethnically Diverse Populations | Pediatric CIRB | Available to Open |
| AHOD2131 | COG | A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma | Pediatric CIRB | Available to Open |
| AALL03N1 | COG | Understanding the Ethnic and Racial Differences in Survival in Children with Acute Lymphoblastic Leukemia | Pediatric CIRB | Completed |
| ACCL0935 | COG | Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk | Pediatric CIRB | Completed |
| ADVL1521 | COG | A Phase 2 Study of the MEK inhibitor Trametinib (IND #119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia | Pediatric CIRB | Available to Open |
| ARST1431 | COG | A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) | Pediatric CIRB | Available to Open |
| ANHL2121 | COG | Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis | Pediatric CIRB | Available to Open |